BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 13/11/2024

FDA Clears Path for Abbreviated New Drug Applications for NUPLAZID

The FDA has determined that NUPLAZID tablet, equivalent to 17 milligrams of base, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.

Source: Federal Register — Food and Drug AdministrationOpen original release →